APOA1 and neoplasm: Interestingly, this SR-BI-targeting strategy was also extended to the encapsulation and delivery of the hydrophilic drug, doxorubicin (Yuan et al., 2013), wherein the efficient (>70%) loading of drug within rHDL halved its IC50 in hepatocellular carcinoma (HCC) cells, yielded sustained drug release, and reduced tumor size in an apoA-I-dependent manner.